Ribavirin or CpG DNA sequence-modulated dendritic cells decrease the IgE level and airway inflammation

Dian Jung Chiang, Yi Ling Ye, Wei Li Chen, Yueh Lun Lee, Ni Yun Hsu, Bor Luen Chiang

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Asthma is an allergic disease that is characterized by the imbalance between Th1 and Th2 cells and by the predominant Th2-type immune response. In this study, we investigated the application of dendritic cell (DCs)-based immunotherapy in modulating the immune response of allergic diseases. DCs incubated with ovalbumin (OVA), OVA plus ribavirin, OVA plus CpG-oligodeoxynucleotides (ODN 1826), or OVA plus non-CpG-ODN (ODN 1745) for 48 hours were injected intravenously into four corresponding groups of BALB/c mice. All of the mice were then immunized with OVA intraperitoneally 7 days later to establish an animal model of asthma. Serum levels of OVA antibody, airway hyperresponsivness, cell composition and cytokine levels in the bronchoalveolar lavage fluid, and cytokine profiles of spleen cells were analyzed. The data showed that ribavirin and ODN 1826 increased interleukin-12 synthesis and inhibited interleukin-10 production. ODN 1826 could also enhance the expression of B7.1, B7.2, major histocompatibility complex I, and major histocompatibility complex II molecules. Furthermore, the DCs modulated by ribavirin and ODN 1826 could downregulate the Th2-type immune response in vivo and could alleviate airway inflammation. This study elucidated the effect of ribavirin and CpG-ODN on DCs and demonstrated that in vitro modulated DCs might be a potential therapeutic approach for asthma.

Original languageEnglish
Pages (from-to)575-580
Number of pages6
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume168
Issue number5
DOIs
Publication statusPublished - Sep 1 2003
Externally publishedYes

Fingerprint

Ribavirin
Ovalbumin
Dendritic Cells
Immunoglobulin E
Inflammation
Asthma
Major Histocompatibility Complex
Cytokines
Th2 Cells
Th1 Cells
Oligodeoxyribonucleotides
Bronchoalveolar Lavage Fluid
Interleukin-12
Interleukin-10
Immunotherapy
Down-Regulation
Spleen
Animal Models
Antibodies
Serum

Keywords

  • Asthma
  • CpG-ODN
  • Dendritic cells
  • Ribavirin

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Ribavirin or CpG DNA sequence-modulated dendritic cells decrease the IgE level and airway inflammation. / Chiang, Dian Jung; Ye, Yi Ling; Chen, Wei Li; Lee, Yueh Lun; Hsu, Ni Yun; Chiang, Bor Luen.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 168, No. 5, 01.09.2003, p. 575-580.

Research output: Contribution to journalArticle

Chiang, Dian Jung ; Ye, Yi Ling ; Chen, Wei Li ; Lee, Yueh Lun ; Hsu, Ni Yun ; Chiang, Bor Luen. / Ribavirin or CpG DNA sequence-modulated dendritic cells decrease the IgE level and airway inflammation. In: American Journal of Respiratory and Critical Care Medicine. 2003 ; Vol. 168, No. 5. pp. 575-580.
@article{81af2675370c4eb3acae2cb20491a7fc,
title = "Ribavirin or CpG DNA sequence-modulated dendritic cells decrease the IgE level and airway inflammation",
abstract = "Asthma is an allergic disease that is characterized by the imbalance between Th1 and Th2 cells and by the predominant Th2-type immune response. In this study, we investigated the application of dendritic cell (DCs)-based immunotherapy in modulating the immune response of allergic diseases. DCs incubated with ovalbumin (OVA), OVA plus ribavirin, OVA plus CpG-oligodeoxynucleotides (ODN 1826), or OVA plus non-CpG-ODN (ODN 1745) for 48 hours were injected intravenously into four corresponding groups of BALB/c mice. All of the mice were then immunized with OVA intraperitoneally 7 days later to establish an animal model of asthma. Serum levels of OVA antibody, airway hyperresponsivness, cell composition and cytokine levels in the bronchoalveolar lavage fluid, and cytokine profiles of spleen cells were analyzed. The data showed that ribavirin and ODN 1826 increased interleukin-12 synthesis and inhibited interleukin-10 production. ODN 1826 could also enhance the expression of B7.1, B7.2, major histocompatibility complex I, and major histocompatibility complex II molecules. Furthermore, the DCs modulated by ribavirin and ODN 1826 could downregulate the Th2-type immune response in vivo and could alleviate airway inflammation. This study elucidated the effect of ribavirin and CpG-ODN on DCs and demonstrated that in vitro modulated DCs might be a potential therapeutic approach for asthma.",
keywords = "Asthma, CpG-ODN, Dendritic cells, Ribavirin",
author = "Chiang, {Dian Jung} and Ye, {Yi Ling} and Chen, {Wei Li} and Lee, {Yueh Lun} and Hsu, {Ni Yun} and Chiang, {Bor Luen}",
year = "2003",
month = "9",
day = "1",
doi = "10.1164/rccm.2205005",
language = "English",
volume = "168",
pages = "575--580",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "5",

}

TY - JOUR

T1 - Ribavirin or CpG DNA sequence-modulated dendritic cells decrease the IgE level and airway inflammation

AU - Chiang, Dian Jung

AU - Ye, Yi Ling

AU - Chen, Wei Li

AU - Lee, Yueh Lun

AU - Hsu, Ni Yun

AU - Chiang, Bor Luen

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Asthma is an allergic disease that is characterized by the imbalance between Th1 and Th2 cells and by the predominant Th2-type immune response. In this study, we investigated the application of dendritic cell (DCs)-based immunotherapy in modulating the immune response of allergic diseases. DCs incubated with ovalbumin (OVA), OVA plus ribavirin, OVA plus CpG-oligodeoxynucleotides (ODN 1826), or OVA plus non-CpG-ODN (ODN 1745) for 48 hours were injected intravenously into four corresponding groups of BALB/c mice. All of the mice were then immunized with OVA intraperitoneally 7 days later to establish an animal model of asthma. Serum levels of OVA antibody, airway hyperresponsivness, cell composition and cytokine levels in the bronchoalveolar lavage fluid, and cytokine profiles of spleen cells were analyzed. The data showed that ribavirin and ODN 1826 increased interleukin-12 synthesis and inhibited interleukin-10 production. ODN 1826 could also enhance the expression of B7.1, B7.2, major histocompatibility complex I, and major histocompatibility complex II molecules. Furthermore, the DCs modulated by ribavirin and ODN 1826 could downregulate the Th2-type immune response in vivo and could alleviate airway inflammation. This study elucidated the effect of ribavirin and CpG-ODN on DCs and demonstrated that in vitro modulated DCs might be a potential therapeutic approach for asthma.

AB - Asthma is an allergic disease that is characterized by the imbalance between Th1 and Th2 cells and by the predominant Th2-type immune response. In this study, we investigated the application of dendritic cell (DCs)-based immunotherapy in modulating the immune response of allergic diseases. DCs incubated with ovalbumin (OVA), OVA plus ribavirin, OVA plus CpG-oligodeoxynucleotides (ODN 1826), or OVA plus non-CpG-ODN (ODN 1745) for 48 hours were injected intravenously into four corresponding groups of BALB/c mice. All of the mice were then immunized with OVA intraperitoneally 7 days later to establish an animal model of asthma. Serum levels of OVA antibody, airway hyperresponsivness, cell composition and cytokine levels in the bronchoalveolar lavage fluid, and cytokine profiles of spleen cells were analyzed. The data showed that ribavirin and ODN 1826 increased interleukin-12 synthesis and inhibited interleukin-10 production. ODN 1826 could also enhance the expression of B7.1, B7.2, major histocompatibility complex I, and major histocompatibility complex II molecules. Furthermore, the DCs modulated by ribavirin and ODN 1826 could downregulate the Th2-type immune response in vivo and could alleviate airway inflammation. This study elucidated the effect of ribavirin and CpG-ODN on DCs and demonstrated that in vitro modulated DCs might be a potential therapeutic approach for asthma.

KW - Asthma

KW - CpG-ODN

KW - Dendritic cells

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=0042877077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042877077&partnerID=8YFLogxK

U2 - 10.1164/rccm.2205005

DO - 10.1164/rccm.2205005

M3 - Article

VL - 168

SP - 575

EP - 580

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 5

ER -